Thomas Force

formació a: Harvard Medical School

ocupació: investigador

Sèrie

There is nothing here

Create a new serie

Treballs

There is nothing here

Create a new work

Articles 94

Date

Títol

Autors

2016-02-03

Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue

Pradeep K Luther, Thomas Streichert, Thomas Force
2016-03-14

Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy

James R. Woodgett, Hind Lal, Thomas Force, Firdos Ahmad, Shan Parikh, Santhanam Shanmughapriya
2015-01-02

The GSK-3 family as therapeutic target for myocardial diseases

Hind Lal, Thomas Force, James R. Woodgett, Firdos Ahmad
2015-08-24

Group IVA Cytosolic Phospholipase A2 Regulates the G2-to-M Transition by Modulating the Activity of Tumor Suppressor SIRT2

Thomas Force, Joseph V Bonventre
2015-01-12

Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury

Thomas Force, Munir Pirmohamed
2015-12-01

Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery

Thomas Force, Brian Druker
2014-10-01

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Maurizio Galderisi, Luigi P Badano, Thor Edvardsen, Thomas Force, Daniela Maria Cardinale, Andreia Magalhães
2014-04-09

Sorafenib cardiotoxicity increases mortality after myocardial infarction

Hind Lal, Mary Barbe, Thomas Force, Steven R Houser
2014-05-29

Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014)

Luca Gianni, Giorgio Minotti, Daniela Maria Cardinale, Thomas Force, Sandra M. Swain, Sarah Darby, Steven Colan, Leontien C Kremer, Flora E van Leeuwen
2014-08-01

Cardiomyocyte-specific deletion of Gsk3α mitigates post-myocardial infarction remodeling, contractile dysfunction, and heart failure

Erhe Gao, Hind Lal, Thomas Force, James R. Woodgett, Firdos Ahmad
2014-06-16

Imatinib activates pathological hypertrophy by altering myocyte calcium regulation

Thomas Force, Steven R Houser
2014-09-10

Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities

Thomas Force
2014-06-04

Cardiac fibroblast glycogen synthase kinase-3β regulates ventricular remodeling and dysfunction in ischemic heart

Hind Lal, James R. Woodgett, Thomas Force, Firdos Ahmad
2014-09-01

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Maurizio Galderisi, Ana Barac, Luigi P Badano, Thor Edvardsen, Thomas Force, Andreia Magalhães
2014

Troponin I-Interacting Protein Kinase

Firdos Ahmad, Hind Lal, Thomas Force
2013-06-27

Differential activation of cultured neonatal cardiomyocytes by plasmalemmal versus intracellular G protein-coupled receptor 55

Thomas Force, Mary E. Abood
2013-12-12

MICU1 motifs define mitochondrial calcium uniporter binding and activity

Thomas Force
2013-01-01

Cancer genetics and the cardiotoxicity of the therapeutics

Thomas Force, Hind Lal, Kyle L Kolaja
2013-08-01

Emerging paradigms in cardiomyopathies associated with cancer therapies

Thomas Force
2013-08-29

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure

Thomas Force, Stephan von Haehling, Hind Lal, Frederic Jaisser, Thomas Thum, Berthold Hocher, Stefan D. Anker, Elena Kaschina, Denise Hilfiker-Kleiner, Andrew Coats, Mareike S Pötsch, Anika Tschirner, Sandra Palus, Wolfram Doehner, Karoline von Websky, Josep M. Argilés
2013-03-15

GSK-3α is a central regulator of age-related pathologies in mice

James R. Woodgett, Thomas Force, Hind Lal, Theresa A Freeman, Firdos Ahmad
2013-06-11

Mechanism-based engineering against anthracycline cardiotoxicity

Thomas Force, Yibin Wang
2012-01-01

Protein Kinase Signaling at the Crossroads of Myocyte Life and Death in Ischemic Heart Disease

Thomas Force, John W. Elrod
2012-02-01

Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors

Thomas Force
2012-02-01

The Heart Failure Society of America in 2020: a vision for the future

Thomas Force, Mandeep R. Mehra, Mariann R. Piano, Douglas L. Mann, Clyde Yancy, Randall C Starling, Steven R Houser
2012-03-26

Double-edged sword of the new cancer therapeutics.

Thomas Force
2011-11-15

Glycogen synthase kinase-3α limits ischemic injury, cardiac rupture, post-myocardial infarction remodeling and death

Erhe Gao, Hind Lal, Thomas Force, James R. Woodgett, Firdos Ahmad
2011-08-01

Cytosolic phospholipase A(2)α protects against ischemia/reperfusion injury in the heart

Raisa Serpi, Thomas Force
2011-10-27

Wnt signaling exerts an antiproliferative effect on adult cardiac progenitor cells through IGFBP3

Jung-Kyu Han, Thomas Force, Randall T. Moon
2011-10-13

A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity

Adam P. Dicker, Thomas Force
2011-01-01

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

Thomas Force, Gianluigi Condorelli, Ajay M. Shah, Johann Wojta, Emilio Hirsch, Munir Pirmohamed, Evandro de Azambuja, Denise Hilfiker-Kleiner, Gitte Neubauer, Metin Avkiran, Gilles W De Keulenaer, Jean-Luc Balligand, Piotr Ponikowski, Faiez Zannad, Stefan D. Anker, Burkert Pieske, Thomas Eschenhagen, Mathias Rauchhaus
2011-02-01

Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes

Thomas Force

Human - wd:Q37839022

Welcome to Inventaire

la biblioteca dels teus amics i comunitats

saber més